Slide-Deoxyribonucleic Acid (DNA)-Sequencing for Copy Number Mapping Global Market Report 2026

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market size has grown rapidly in recent years. It will grow from $0.38 billion in 2025 to $0.43 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to advances in fluorescent labeling techniques, adoption of optical mapping sequencing, increasing cancer genomics research, growth of genetic disease studies, expansion of academic genomics infrastructure.

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market size is expected to see rapid growth in the next few years. It will grow to $0.75 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to integration with ai-driven variant calling, demand for high-throughput imaging, adoption of single-molecule sequencing, growth of personalized medicine applications, expansion of genomic laboratories in emerging markets. Major trends in the forecast period include high-resolution dna mapping, single-cell sequencing integration, automated slide processing, spatial genomics analytics, predictive genomic variation modeling.

The growing demand for precision medicine is anticipated to drive the expansion of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market in the coming years. Precision medicine refers to a healthcare strategy that leverages individual genetic and molecular profiles to inform diagnosis and treatment decisions for enhanced clinical outcomes. The surge in precision medicine adoption is rising due to the increasing global prevalence of complex and chronic diseases that necessitate highly targeted and individualized treatment approaches. Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping addresses this demand by providing detailed analysis of genomic variations that guide patient-specific diagnosis and therapy. It enables targeted treatments, improves risk evaluation, and strengthens clinical decision-making for more personalized and effective care. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based educational and advocacy organization, the FDA approved 16 new personalized therapies for rare disease patients in 2023, up from 6 approvals in 2022. Consequently, the growing demand for precision medicine is fueling the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market.

The increasing prevalence of genetic disorders is expected to boost the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market in the future. Genetic disorders are conditions caused by anomalies in an individual’s DNA, such as mutations, deletions, or chromosomal alterations that disrupt normal biological functions. The rise in genetic disorders, driven by heightened awareness and advanced diagnostic capabilities, is resulting in more cases being detected, enabling earlier intervention and management of inherited conditions. Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping aids in managing genetic disorders by allowing accurate identification of genomic variations, including duplications and deletions, contributing to disease. It supports early diagnosis, guides personalized treatment plans, and improves monitoring of disease progression for better patient outcomes. For instance, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 individuals living with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed annually. Therefore, the increasing prevalence of genetic disorders is propelling the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market.

The rising healthcare expenditure is projected to accelerate the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market going forward. Healthcare expenditure encompasses the total financial resources allocated to medical services, including treatments, hospital care, medications, and public health programs, by governments, businesses, and individuals. The surge in healthcare spending is driven by the growing prevalence of chronic diseases that require long-term and costly interventions. Increased healthcare expenditure supports slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping by facilitating greater investment in advanced genomic technologies, infrastructure, and skilled workforce. It promotes broader adoption in clinical environments, expedites research and diagnostic initiatives, and enhances accessibility to personalized management of genetic disorders. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market.

Major companies operating in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market are Thermo Fisher Scientific, Becton Dickinson Company (BD), Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., 10x Genomics Inc., BGI Genomics Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Fluidigm Corporation, Roche Sequencing Solutions, Mission Bio Inc., Twist Bioscience Corp., Genapsys Inc., Phase Genomics Inc., Singular Genomics Systems Inc.

North America was the largest region in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market consists of revenues earned by entities by providing services such as spatial transcriptomics analysis, copy number variation analysis services, bioinformatics data analysis, library preparation, sample processing, tissue slide preparation, genomic data interpretation, and research consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market also includes sales of DNA sequencing instruments, spatial sequencing platforms, tissue slide arrays, microarray slides, library preparation kits, DNA extraction kits, reagents and assay kits, sequencing flow cells, microfluidic chips, imaging systems, and sample preservation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping is a laboratory method that sequences DNA on microscope slides to detect variations in the number of copies of specific genomic regions. This technique identifies duplications, deletions, or amplifications, providing insights into genetic disorders, cancer progression, and other genomic anomalies. It allows spatially precise, high-resolution analysis, enabling researchers to directly map genomic alterations within tissue samples.

The key workflow types of slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping include sample preparation, sequencing and imaging, and data analysis and interpretation. Sample preparation involves treating and processing biological, chemical, or environmental samples to make them suitable for analysis. Product types include instruments, consumables, software, and services, compatible with sample types such as fresh frozen (FF) tissues, formalin-fixed paraffin-embedded (FFPE) tissues, organoids, and 3D cell cultures. Workflows cover sample preparation, sequencing and imaging, and data analysis and interpretation. Applications include cancer genomics, genetic disease research, prenatal diagnostics, and other areas, serving hospitals and diagnostic centers, academic and research institutes, biotechnology and pharmaceutical companies, contract research organizations, and genomic laboratories.

Tariffs have affected the slide-DNA sequencing for copy number mapping market by increasing costs of imported instruments, reagents, and software platforms. The instruments and consumables segments are most impacted, particularly in regions like North America and Europe that rely heavily on imports for advanced genomic equipment. While tariffs have raised operational costs, they are also encouraging domestic manufacturing initiatives and innovation in cost-efficient sequencing solutions, promoting local industry development and reducing supply chain dependency.

The slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market research report is one of a series of new reports that provides slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market statistics, including slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping industry global market size, regional shares, competitors with a slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market share, detailed slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market segments, market trends and opportunities, and any further data you may need to thrive in the slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping industry. This slide-deoxyribonucleic acid (DNA)-sequencing for copy number mapping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.